Aminoglycosides Market

Global Aminoglycosides Market:

The global aminoglycosides market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.66% during 2024-2032. The rising number of incidences associated with tuberculosis is stimulating the market.

Aminoglycosides Market Analysis:

• Major Market Drivers: The increasing geriatric population susceptible to bacterial infections is one of the key factors stimulating the market.
• Key Market Trends: The growing demand for effective animal healthcare solutions is acting as a significant growth-inducing factor. Moreover, continuous formulation technologies are further catalyzing the market.
• Competitive Landscape: Some of the prominent companies in the market include Huvepharma NV, Kremoint Pharma Pvt. Ltd., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd, and Vega Group company limited, among many others.
• Geographical Trends: The inflating popularity of effective antimicrobial treatment options is fueling the market in Asia Pacific. Besides this, the increasing need for valuable therapeutic agents is also fueling the market.
• Challenges and Opportunities: The risks of developing nephrotoxicity pose a challenge in the market. However, the introduction of efficient delivery methods to minimize the side effects is expected to fuel the market in the coming years.
   

Aminoglycosides Market Trends:

Increasing Personalized Medicine

The rising need for antibiotics that are prescribed and administered is propelling the market. Besides this, advances in diagnostic and genomics tools have enabled healthcare providers to identify the most effective aminoglycoside for each patient, thereby minimizing the risks of ototoxicity and nephrotoxicity. For instance, in March 2024, Insmed Incorporated presented nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego. It included microbiologic data from the ARISE study of ARIKAYCE® in patients with recurrent or newly diagnosed Mycobacterium avium complex (MAC) lung disease who had not started antibiotics.

Rising Regulatory Landscape

Pharmaceutical companies and regulatory bodies are focusing on enhancing the monitoring and safety of aminoglycoside use. New protocols and guidelines to optimize dosing and minimize adverse effects, which is stimulating the market. For example, in February 2024, Cipla Limited received approval from the Central Drugs Standard Control Organization (CDSCO) to promote the novel antibiotic plazomicin, an intravenous aminoglycoside, in India. This is propelling the aminoglycosides market overview.

Growing Popularity of Combination Therapies

Combination therapies involving aminoglycosides are gaining traction to enhance treatment efficacy and combat antibiotic resistance. By pairing aminoglycosides with other antibiotics, healthcare providers can target multiple bacterial mechanisms, thereby reducing the likelihood of resistance development. In July 2024, Orchid Pharma Limited launched its new drug, Cefepime-Enmetazobactam, which has been approved to treat complicated hospital-acquired pneumonia (HAP), urinary tract infections (cUTI), and ventilator-associated pneumonia (VAP) indications. 

Global Aminoglycosides Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the aminoglycosides market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on the product, route of administration, and application.

Breakup by Product:

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Kanamycin
• Others
   

Gentamicin dominates the aminoglycosides market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. According to the report, gentamicin represented the largest market segmentation. 

Gentamicin is a potent aminoglycoside antibiotic used for treating bacterial infections. Xellia Pharmaceuticals provides a range of gentamicin products, including injectable solutions that are adopted in hospital settings.

Breakup by Route of Administration:

• Injectables (Parenteral)
• Intra-mammary
• Topical
• Oral
• Others
   

Injectables (Parenteral) exhibited a clear dominance in the aminoglycosides market demand

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes injectables (parenteral), intra-mammary, topical, oral, and others. According to the report, injectables (parenteral) represented the largest market segmentation.

The rising need for developing safer and effective treatment options for patients is driving the segment's growth. For instance, Hikma Pharmaceuticals expanded its portfolio designed for critical care environments.

Breakup by Application:

• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Others
   

Respiratory diseases accounted for the largest aminoglycosides market revenue

The report has provided a detailed breakup and analysis of the market based on the application. This includes veterinary, skin infection, respiratory diseases, UTI and pelvic diseases, and others. According to the report, respiratory diseases represented the largest market segmentation.

The growing requirement for combating respiratory diseases is catalyzing the market. Additionally, it aimed to optimize the delivery of these antibiotics directly to the lungs.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Asia Pacific exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share.

The increasing incidences of chronic respiratory infections are fueling the aminoglycosides market statistics in Asia Pacific. Apart from this, the expanding pharmaceutical industry is also acting as another significant growth-inducing factor. According to IMARC, the India pharmaceutical market size reached US$ 54.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 163.1 Billion by 2032, exhibiting a growth rate (CAGR) of 12.3% during 2024-2032. 

Competitive Landscape:

 The rising investments in developing new delivery methods, exploring novel applications, and improving existing aminoglycoside formulations are propelling the market. Companies are also conducting clinical trials to assess the safety, which is positively influencing the aminoglycosides market outlook.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major aminoglycosides market companies have also been provided. Some of the key players in the market include:

• Huvepharma NV
• Kremoint Pharma Pvt. Ltd.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Vega Group company limited
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Aminoglycosides Market Recent Developments:

• July 2024: Orchid Pharma Limited launched its new drug, Cefepime-Enmetazobactam, which has been approved to treat complicated hospital-acquired pneumonia (HAP), urinary tract infections (cUTI), and ventilator-associated pneumonia (VAP) indications. 
• March 2024: Insmed Incorporated presented nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego. It included microbiologic data from the ARISE study of ARIKAYCE® in patients with recurrent or newly diagnosed Mycobacterium avium complex (MAC) lung disease who had not started antibiotics.
• February 2024: Cipla Limited received approval from the Central Drugs Standard Control Organization (CDSCO) to promote the novel antibiotic plazomicin, an intravenous aminoglycoside, in India.

Aminoglycosides Market Report Scope:

Key Questions Answered in This Report:

• How has the global aminoglycosides market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global aminoglycosides market?
• What is the impact of each driver, restraint, and opportunity on the global aminoglycosides market growth?
• What are the key regional markets?
• Which countries represent the most attractive aminoglycosides market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the aminoglycosides market?
• What is the breakup of the market based on the route of administration?
• Which is the most attractive route of administration in the aminoglycosides market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the aminoglycosides market?
• What is the competitive structure of the global aminoglycosides market? 
• Who are the key players/companies in the global aminoglycosides market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the aminoglycosides market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global aminoglycosides market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the aminoglycosides industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.